Q32 Bio Inc. (QTTB) Stock Price & How to Invest

Q32 Bio Inc. is a clinical-stage biotechnology company focused on alopecia areata (AA) and other autoimmune and inflammatory diseases. Its lead and effectively only clinical program is bempikibart (ADX-914), a fully human monoclonal antibody that blocks the interleukin-7 receptor alpha chain and therefore shuts down signaling from both IL-7 and TSLP, two pathways implicated in the T-cell attack on hair follicles. The company reached the public market by reverse-merging into Homology Medicines in March 2024, which is why the CIK on EDGAR still carries the old FIXX ticker, and it trades on the Nasdaq Capital Market with about 24 employees under CEO Jodie Morrison. Its history since then has been a sequence of narrowing decisions: bempikibart missed in atopic dermatitis (the SIGNAL-AD trial, topline December 2024), the company restructured in February 2025 to focus on AA, and in November 2025 it sold the entire ADX-097 complement program to Akebia Therapeutics. What remains is bempikibart, a preclinical half-life-extended follow-on called ADX-914-XL, and a retained tissue-targeted complement platform (ADX-096 and related molecules) that management describes as under strategic review.

The investment picture turns on two facts that arrived in July 2026. First, Q32 reported 36-week topline results from SIGNAL-AA Part B, an open-label trial in 33 patients with severe or very severe AA: a mean SALT score reduction of ~35.3% in the modified intent-to-treat population, with ~40.0% (10 of 25) achieving a SALT20 response in the mITT analysis and ~30.3% (10 of 33) in the full intent-to-treat set. Second, the company sold ~6.03 million shares at $18.25 plus pre-funded warrants for another ~4.93 million shares, taking in ~$187.6 million net. Added to the ~$106.3 million on hand at June 30, that is roughly ~$294 million against a market value near ~$473 million at ~$15.90 per share, and the company states the money is sufficient to reach topline Phase 3 results of the registration-directed program it intends to start in the first half of 2027. The reported ~$53.7 million of trailing revenue and the resulting single-digit trailing P/E are accounting artifacts, not a business: they come from derecognizing a ~$55.0 million refund liability owed to Amgen in the fourth quarter of 2025. Q32 has never recorded a dollar of product revenue and does not expect to for years.

The concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. The July data came from an open-label single-arm trial of 33 patients with no placebo control, and the headline numbers rest on a 25-patient mITT population, so eight of the 33 enrolled patients sit outside the primary analysis and the ITT figures are materially lower (~30.3% versus ~40.0% on SALT20); alopecia areata trials have a long history of placebo responses and spontaneous regrowth that a single-arm design cannot separate out. The economics of a future partnership are encumbered, because bempikibart is in-licensed from Bristol-Myers Squibb under a 2019 agreement that entitles BMS to development and regulatory milestones of ~$32 million to ~$49 million per indication for the first three indications, up to ~$215 million of commercial milestones, royalties from mid-single digits to ~10%, and up to ~60% of any sublicense income, a share that falls only as the program advances. Dilution has been continuous and is not finished: the share count went from ~12.9 million at the end of 2025 to ~29.8 million by August 3, 2026 through a February registered direct, a March ATM with Cantor Fitzgerald, a May private placement at $8.00 and the July follow-on at $18.25, there are ~6.1 million pre-funded warrants outstanding on top of that, and the company states plainly that its cash will not carry any program to regulatory approval. Finally, the listing itself has been fragile before, with a May 19, 2025 Nasdaq notice for falling below the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1) that was only cured on the strength of the Q4 2025 accounting gain and subsequent raises, and a stock that ranged from ~$1.62 to ~$23.57 within twelve months is not one where position sizing is a detail.

4 analysts publish price targets on QTTB, averaging $42.75 against a $15.97 price as of August 2026, or +167.7%. The published targets run from $36.00 to $59.00, a moderate spread, and the ratings split 5 buy, 0 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full QTTB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Q32 Bio Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Bempikibart and the path to a registration-directed program. SIGNAL-AA Part B enrolled 33 patients with baseline SALT scores of 50 to 100, dosed 200mg weekly for four loading doses and then every other week through Week 36, with ~36.4% having prior exposure to oral JAK inhibitors. The most optimistic published target, $59.00, assumes this works close to its best case.

The case against. The concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. The most pessimistic target, $36.00, is roughly what QTTB is worth if this bites instead.

Read the full bull and bear case on QTTB, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Q32 Bio Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$53.7 million, all of it recognized in the fourth quarter of 2025 and none of it product revenue: it is the derecognition of a ~$55.0 million refund liability from the terminated Horizon collaboration, settled with Amgen on November 7, 2025 for ~553,695 shares. Revenue in the first half of 2026 was ~$0
• Loss rate: Net loss of ~$8.9 million in Q2 2026 and ~$16.6 million for the first half, on operating expenses of ~$16.8 million (R&D ~$7.5 million, G&A ~$9.4 million); net cash used in operations was ~$9.4 million for the half versus ~$23.1 million a year earlier. Accumulated deficit stands at ~$221.5 million
• Cash and runway: ~$106.3 million of cash and equivalents at June 30, 2026, plus ~$187.6 million net from the July 16 follow-on, for roughly ~$294 million before third-quarter spending. Management states this funds operations through topline Phase 3 results of the planned registration-directed program, and explicitly not through regulatory approval
• Balance sheet: Total assets ~$115.9 million against total liabilities ~$10.0 million and stockholders' equity ~$105.9 million at June 30, 2026, all before the July raise. Debt-free since the ~$6.8 million Silicon Valley Bank venture-debt payoff on June 24, 2026
• Program spend: Direct R&D on bempikibart was ~$2.4 million in Q2 2026 and ~$3.7 million for the half; ADX-097 spending fell to ~$0 after the Akebia sale, from ~$1.5 million in the first half of 2025. The company employs ~24 people
• Market pricing: ~$15.90 per share for a market value near ~$473 million on ~29,769,466 shares outstanding as of August 3, 2026, with ~21.0 million of public float and ~6.1 million pre-funded warrants outstanding on top. Counting those warrants, equity value is closer to ~$570 million and enterprise value near ~$276 million. 52-week range ~$1.62 (September 4, 2025) to ~$23.57 (July 14, 2026)

Figures are approximate, tied to August 2026 and drawn from the Q2 2026 10-Q filed August 5, 2026 and the fiscal 2025 10-K, so check live data before acting on any of them. Two screen-level numbers on QTTB are misleading and worth discarding: the ~5.3x trailing P/E and the ~8.8x price-to-sales both derive from the ~$53.7 million of one-time non-cash collaboration revenue and the ~$29.8 million of 2025 net income it produced, and neither describes an operating business. The number that carries information is enterprise value, roughly ~$276 million once the ~$294 million of pro forma cash is netted against the fully-funded equity value, which is what the market is assigning to bempikibart, the retained complement platform and the Akebia royalty stream combined.

Other names that sit close to QTTB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get QTTB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so QTTB sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where QTTB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Q32 Bio in August 2026 is a single-asset autoimmune bet whose balance sheet finally matches its ambition, priced at roughly $276 million of enterprise value on 33 patients of open-label data and a Phase 3 that has not started.

Whether QTTB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is QTTB a buy or a sell?, and where the stock could go from here in the QTTB stock forecast.

For income investors, whether QTTB pays a dividend and how the payout looks is covered in does QTTB pay a dividend? And to weigh QTTB against a peer, read the full side-by-side comparisons: QTTB vs AA and QTTB vs LLY.